Combination of Atazanavir and Raltegravir as Dual Strategy - CARDS STUDY

AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2009年7月24日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•i. Age > 18 years
•ii. Documented HIV infection
•iii. Written informed consent
•iv. Antiretroviral experienced patients
•v. Effective ongoing treatment (HIV-RNA < 50 copies/ml for longer than 6 months and at least for 3 consecutive evaluations).
•vi. Extensive resistance to the current NRTI-backbone, according to genotype, or NRTI-related toxicity for which patient might benefit from switching his/her regimen.
•vii. No documented genotypic resistance to protease inhibitors
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•i. Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviours
•ii. Any ongoing grade 4 laboratory abnormality, but for lipid alterations
•iii. Patients requiring chronic proton pump inhibitors.
•iv. Concomitant treatment with ritonavir as well as with inducers (NNRTI, rifampin, carbamazepine, phenytoin, phenobarbital, valproic acid, etc) or inhibitors (probenecid, etc) of the uridine diphosphate glucuronyl transferase within 2 weeks before the screening visit.
•v. History or suspected poor adherence to HAART.

发起方

AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)